Skip to content

Author

Zhumagazin Zhanabay Derbesinovich

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Immunotherapy and Targeted Therapy for Metastatic Renal Cell Carcinoma

Lenvatinib plus pembrolizumab provides significant improvements in PFS and objective response compared with sunitinib, while nivolumab plus ipilimumab demonstrates durable long-term survival benefits.

Zhumagazin Zhanabay Derbesinovich · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.